Angelo Antonini

Prof. Dr. Angelo Antonini

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
GHGünter U. Höglinger
Günter U. Höglinger
GRGesine Respondek
Gesine Respondek
MSMaria Stamelou
Maria Stamelou
CKCarolin Kurz
Carolin Kurz
KJKeith A. Josephs
Keith A. Josephs
FGfor the Movement Disorder Society–endorsed PSP Study Group
for the Movement Disorder Society–endorsed PSP Study Group

9 June 2009 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
PBPaolo Barone
Paolo Barone
Angelo AntoniniAngelo Antonini
Angelo Antonini
CCCarlo Colosimo
Carlo Colosimo
RMRoberto Marconi
Roberto Marconi
LMLetterio Morgante
Letterio Morgante
PDPaolo Del Dotto
Paolo Del Dotto

1 February 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
COC Warren Olanow
C Warren Olanow
KKKarl Kieburtz
Karl Kieburtz
POPer Odin
Per Odin
AEAlberto J Espay
Alberto J Espay
DSDavid Standaert
David Standaert
Angelo AntoniniAngelo Antonini
Angelo Antonini

22 December 2012 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ABAlfredo Berardelli
Alfredo Berardelli
GWG. K. Wenning
G. K. Wenning
Angelo AntoniniAngelo Antonini
Angelo Antonini
DBD. Berg
D. Berg
BBB. R. Bloem
B. R. Bloem
MVM. Vidailhet
M. Vidailhet

5 May 2023 in Movement Disorders
Verified
Journal Article
Open access
SJStefanie T. Jost
Stefanie T. Jost
MKMarie‐Ann Kaldenbach
Marie‐Ann Kaldenbach
Angelo AntoniniAngelo Antonini
Angelo Antonini
PMPablo Martinez‐Martin
Pablo Martinez‐Martin
LTLars Timmermann
Lars Timmermann
TGthe International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
the International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.Objectives: To update LED conversion formulae based on a systematic review.Methods: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.Results: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.Conclusions: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 December 2011 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
POPer Odin
Per Odin
Angelo AntoniniAngelo Antonini
Angelo Antonini
PMPablo Martinez-Martin
Pablo Martinez-Martin